CK Life Sciences

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Retrieved on: 
Thursday, March 28, 2024
TP53, Innovation, Innovation Center station, Patient, Surface plasmon resonance, Artificial intelligence, Cancer, Allele, HLA, CK Life Sciences, AACR, Robotics, MHC, MHC-II, Therapy, Cosmetics, Data, Probability, Peptide, Vaccine

The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.

Key Points: 
  • The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
  • "We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy.
  • Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
  • The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides.

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Retrieved on: 
Thursday, March 28, 2024
TP53, Innovation, Innovation Center station, Patient, Surface plasmon resonance, Artificial intelligence, Cancer, Allele, HLA, CK Life Sciences, AACR, Robotics, MHC, MHC-II, Therapy, Cosmetics, Data, Probability, Peptide, Vaccine

The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.

Key Points: 
  • The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
  • "We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy.
  • Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
  • The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides.

Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis

Retrieved on: 
Thursday, February 15, 2024
Diabetes, Obesity, Cancer, CK Life Sciences, Goel, Risk, CK Hutchison Holdings, MicroRNA, Biomarker, History, Therapy, PDAC, Tobacco, Patient, Pancreas, Disease, Diagnosis, Machine learning, AGAF, Molecular diagnostics, Pancreatic cancer, Mortality, Abdominal cavity, Research, Insurance, Medical imaging

LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC).

Key Points: 
  • LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC).
  • This license agreement marks a pivotal step with PharusDx to develop and commercialize a version of its OncoSweep™ liquid biopsy screening for the early detection of PDAC.
  • The poor survival rate is mainly due to late-stage diagnosis, attributed to the pancreas' deep location within the abdominal cavity.
  • The current challenge of asymptomatic early diagnosis of PDAC is anticipated to be addressed by PharusDx's liquid biopsy miRNA test: OncoSweep™.

XtalPi and CK Life Sciences to collaborate in AI-empowered tumour vaccine research and development, opening a new paradigm for scientific innovation

Retrieved on: 
Friday, November 25, 2022
CK Life Sciences, Immunotherapy, FDA, BCG, Automation, Sale, R, Marketing, Stock exchange, Cancer, Guangdong-Hong Kong-Macau Greater Bay Area, Hong Kong Stock Exchange, Algorithm, Drug development, Melanoma, Machine learning, Patient, Quality of life, Physics, TAA, Disease, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hetao, Mortality, Artificial intelligence, ID4, Bladder cancer, TSA, Food, Pharmaceutical industry, Vaccine, Fine chemical, AI

SHENZHEN & HONG KONG, China, Nov. 24, 2022 /PRNewswire/ -- XtalPi announced today that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumour vaccine R&D platform to improve the discovery and design capabilities of tumour vaccines and accelerate the development of more vaccine types. The goal of this collaboration is to realize precision treatment for patients worldwide.

Key Points: 
  • XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumour vaccine R&D platform to improve the discovery and design capabilities of tumour vaccines and accelerate the development of more vaccine types.
  • Currently, the design and preclinical development process for tumour vaccines is complex and lengthy, hindering the efficiency and success rate of tumour vaccine research and development.
  • We believe the AI cancer vaccine platform jointly developed by CK Life Sciences and XtalPi will inspire the global scientific community to progress vaccine research and development and fast-track key development milestones for cancer vaccines.
  • Dr. Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences, comments: "The R&D of tumour vaccines is one of the key development directions of CK Life Sciences.

Pharus, Inc. Names Philip C. Huang as Company CEO, Becomes Newest Player in Cancer Liquid Biopsy Market

Retrieved on: 
Monday, October 3, 2022
Algorithm, Solution, VP, Cancer, Liquid biopsy, Mirna, Time, Physician, ASCO, Technology, Precision medicine, Industry, Stanford University, Chemical engineering, MBA, CK Life Sciences, Roche, CK Hutchison Holdings, MicroRNA, CA, Roche Diagnostics, INSEAD, Philip, Leadership, Patient, MIT, Biomarker, Diagnosis, American Society of Clinical Oncology, Machine learning, Society, EKF Diagnostics, Data analysis, Medical imaging

LOS ANGELES, Oct. 3, 2022 /PRNewswire/ -- Pharus, Inc. ("PharusDx"), a new diagnostics company spun out from Hsinchu, Taiwan-based Quark Biosciences, has named Philip Huang as its Chief Executive Officer. PharusDx creates solutions for the early detection of cancer and is currently developing its OncoSweep™ Multi-Cancer Early Detection (MCED) liquid biopsy test as well as single-cancer liquid biopsy tests that evaluate microRNA (miRNA) within the body.

Key Points: 
  • PharusDx creates solutions for the early detection of cancer and is currently developing its OncoSweepMulti-Cancer Early Detection (MCED) liquid biopsy test as well as single-cancer liquid biopsy tests that evaluate microRNA (miRNA) within the body.
  • Before joining Roche, Mr. Huang was Vice President of Global Business Development for EKF Diagnostics, a UK point-of-care diagnostics company, where he led corporate strategy and solidified strategic partnerships.
  • PharusDx is entering the precision medicine market with the goal of changing cancer diagnosis, so that medical professionals can detect and treat cancer early, before it progresses to advanced disease.
  • Using OncoSweepMCED and single-cancer liquid biopsy tests, physicians can find circulating biomarkers for multiple forms of cancer by testing blood or other body fluid samples.

Global Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Forecasts, 2030 - Market Penetration, Developments, and Diversification; Marketed & Emerging Drugs, and Competitive Landscape Assessment - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Pharmaceutical, Health, Oncology, Tetrodotoxin, USD, Chronic pain, CIPN, CK, Diagnosis, Cancer, Investment, Global, Adoption, Pfizer, Hoffmann-La Roche, Prevalence, Hyco International Inc, Research report, SWOT, Risk, Cancer pain, Population, CK Life Sciences, COVID-19, TTX, Growth, R, Awareness, Market development, Video game, Fine chemical, Pharmaceutical industry, Retail, Carbon fibers

Based on region, the Global Chemotherapy-Induced Peripheral Neuropathy market is divided into Europe, North America, Asia-Pacific, Middle East & Africa, and South America.

Key Points: 
  • Based on region, the Global Chemotherapy-Induced Peripheral Neuropathy market is divided into Europe, North America, Asia-Pacific, Middle East & Africa, and South America.
  • Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the Global Chemotherapy-Induced Peripheral Neuropathy market have been provided in this research report.
  • The report answers questions such as:
    What is the market size and forecast of the Global Chemotherapy-Induced Peripheral Neuropathy Market?
  • What is the market share of the leading players in the Global Chemotherapy-Induced Peripheral Neuropathy Market?

Pitcher Earns Distinction as Best-in-Class for Interactive Customer Presentations in POI’s 2021 Retail Sales Execution Vendor Panorama

Retrieved on: 
Tuesday, September 14, 2021
Interactive customer evaluation, CEO, Efficiency, Technology, Research, List of life sciences, Council for Scientific and Industrial Research – Ghana, Industry, POI, Environment, Pitcher, Financial services, Logic, CK Life Sciences, Interest, GLOBE, Final good, Life, ROI, Sales, Mobile phone

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Pitcher , the omnichannel, end-to-end sales enablement platform for enterprises, today announced its Super App has been awarded a Best-in-Class distinction for Interactive Customer Presentations in the Promotion Optimization Institute s 2021 Vendor Panorama for Retail Sales Execution and Monitoring in Consumer Goods.

Key Points: 
  • NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Pitcher , the omnichannel, end-to-end sales enablement platform for enterprises, today announced its Super App has been awarded a Best-in-Class distinction for Interactive Customer Presentations in the Promotion Optimization Institute s 2021 Vendor Panorama for Retail Sales Execution and Monitoring in Consumer Goods.
  • POI evaluated 18 vendors and named Pitcher a POI 2021 Best-in-Class Award Recipient for Interactive Customer Presentations.
  • Pitcher is the leading global sales enablement provider of effective customer engagement and sales efficiency through dynamic digital tools, personalized content, and simplified user experience.
  • With deep domain experience, Pitcher serves as a vital partner for sales, field sales, and marketers around the world.

Insights on the Salt Global Market to 2026 - Featuring BASF, Cargill and CIECH Group Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, August 27, 2021
Mining, Minerals, Natural Resources, Company, CAGR, Customer support, Certification, Business Growth Fund, AkzoNobel, Olin Corporation, Growth, Acquisition, CK Life Sciences, Compound annual growth rate, International, Water, Value, Decision-making, Osteoporosis, Compass Minerals, R, Spondyloarthropathy, Investment, Kidney, Strategic management, SE, Use, China National Salt Industry Corporation, McCormick, SaltWorks, Inc., Market share analysis, Seemabaddha, Heart failure, BASF SE, Stroke, COVID-19, USD, Technology, BASF, Retail, Fine chemical

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

Key Points: 
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.
  • What is the market share of the leading vendors in the Global Salt Market?
  • What modes and strategic moves are considered suitable for entering the Global Salt Market?
  • Development of favoured salt like chilli-lime salt, saffron-fennel salt and cinnamon-vanilla salt
    Contribution of salt to high blood pressure, heart failure, kidney problems, fluid retention, stroke and osteoporosis